Atara Biotherap (ATRA)

$5.27 +0.03 (0.57%)
Market Cap 43.10M
Revenue (ttm) 120.77M
Net Income (ttm) 32.69M
EPS (ttm) N/A
PE Ratio 1.68
Forward PE 26.20
Profit Margin 27.07%
Debt to Equity Ratio 0.00
Volume 76,200
Avg Vol 266,368
Day's Range N/A - N/A
Shares Out 8.18M
Stochastic %K 75%
Beta -0.34
Analysts Sell
Price Target $9.33

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to tar...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 623 4211
Address:
1280 Rancho Conejo Blvd, Thousand Oaks, United States
kaos224
kaos224 Apr. 17 at 5:11 PM
$ATRA
0 · Reply
DidiMac
DidiMac Apr. 14 at 2:08 PM
$ATRA
0 · Reply
Niddi
Niddi Apr. 10 at 7:49 PM
$ATRA
0 · Reply
kaos224
kaos224 Apr. 10 at 5:05 PM
$ATRA news out?
0 · Reply
Niddi
Niddi Apr. 9 at 5:23 PM
$ATRA Almost there.
1 · Reply
Niddi
Niddi Apr. 8 at 1:25 PM
$ATRA FDA meeting results coming soon.
1 · Reply
jakewelds20
jakewelds20 Apr. 1 at 12:18 AM
$ATRA class action lawsuit in play. Anyone that bought the stock between may 20 and jan 9 last year 😂😂 i owned this all through the year last year from 6 and sold it into 18 😂😂 reloaded on the major drop and just holding again. Never hold bio into speculative fda shit on a weekend
0 · Reply
Murphy_Dog
Murphy_Dog Mar. 31 at 7:23 PM
$ATRA regulatory update in Q2. Should be soon.
0 · Reply
kaos224
kaos224 Mar. 30 at 10:18 AM
$ATRA why down?
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 27 at 12:30 PM
$ATRA Q4 '25 Earnings Results & Recap Atara Biotherapeutics anticipates its existing capital resources of $8.5M as of December 31, 2025, will be insufficient to fund planned operations for at least the next twelve months.
0 · Reply
Latest News on ATRA
ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 16, 2026, 6:10 PM EDT - 3 days ago

ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

Apr 7, 2026, 6:00 PM EDT - 12 days ago

ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Mar 16, 2026, 4:05 PM EDT - 4 weeks ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Mar 12, 2026, 8:05 AM EDT - 5 weeks ago

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics Provides a Business Update

Feb 23, 2026, 8:00 AM EST - 7 weeks ago

Atara Biotherapeutics Provides a Business Update

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

Jan 12, 2026, 8:00 AM EST - 3 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Nov 12, 2025, 9:00 AM EST - 5 months ago

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Nov 3, 2025, 9:00 AM EST - 5 months ago

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 7 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ASMB CORT

Atara Biotherapeutics Announces Changes to Its Board of Directors

Sep 3, 2025, 6:00 PM EDT - 8 months ago

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Aug 11, 2025, 4:01 PM EDT - 8 months ago

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:57 AM EDT - 9 months ago

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 24, 2025, 8:00 AM EDT - 9 months ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 15, 2025, 8:00 AM EDT - 9 months ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Jul 14, 2025, 8:00 AM EDT - 9 months ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 16, 2025, 8:50 PM EDT - 1 year ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:35 AM EDT - 1 year ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025, 8:30 AM EDT - 1 year ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

May 5, 2025, 5:06 PM EDT - 1 year ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 7, 2025, 4:01 PM EST - 1 year ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 14, 2025, 8:11 AM EST - 1 year ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 11, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 1 year ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 9, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:01 PM EST - 1 year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 7, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 6, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 5, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 4, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 3, 2025, 7:00 AM EST - 1 year ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 30, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 29, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

kaos224
kaos224 Apr. 17 at 5:11 PM
$ATRA
0 · Reply
DidiMac
DidiMac Apr. 14 at 2:08 PM
$ATRA
0 · Reply
Niddi
Niddi Apr. 10 at 7:49 PM
$ATRA
0 · Reply
kaos224
kaos224 Apr. 10 at 5:05 PM
$ATRA news out?
0 · Reply
Niddi
Niddi Apr. 9 at 5:23 PM
$ATRA Almost there.
1 · Reply
Niddi
Niddi Apr. 8 at 1:25 PM
$ATRA FDA meeting results coming soon.
1 · Reply
jakewelds20
jakewelds20 Apr. 1 at 12:18 AM
$ATRA class action lawsuit in play. Anyone that bought the stock between may 20 and jan 9 last year 😂😂 i owned this all through the year last year from 6 and sold it into 18 😂😂 reloaded on the major drop and just holding again. Never hold bio into speculative fda shit on a weekend
0 · Reply
Murphy_Dog
Murphy_Dog Mar. 31 at 7:23 PM
$ATRA regulatory update in Q2. Should be soon.
0 · Reply
kaos224
kaos224 Mar. 30 at 10:18 AM
$ATRA why down?
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 27 at 12:30 PM
$ATRA Q4 '25 Earnings Results & Recap Atara Biotherapeutics anticipates its existing capital resources of $8.5M as of December 31, 2025, will be insufficient to fund planned operations for at least the next twelve months.
0 · Reply
Niddi
Niddi Mar. 20 at 4:05 PM
$ATRA Should touch $7.5-8 once meeting with FDA is done and a statement is issued around end of March IMHO.
0 · Reply
24DV4NC3D
24DV4NC3D Mar. 18 at 8:02 PM
$ATRA ⚡️WHAT DID I SAY?!⚡️ STOCK OF THE DAY - WILDCARD #2 >>>>> #LISTEN! <<<<< >>>>>>> OVERSOLD! <<<<<<<<
0 · Reply
Niddi
Niddi Mar. 17 at 7:30 PM
$ATRA SP held down to accumulate cheap shares. Very obvious from the price movement. It won’t take long to rebound IMHO.
0 · Reply
Pharoh42
Pharoh42 Mar. 17 at 6:44 PM
$ATRA is it an Iranian company or what 🤔
0 · Reply
Niddi
Niddi Mar. 17 at 3:03 PM
$ATRA FDA meeting coming up.
0 · Reply
rombrento
rombrento Mar. 13 at 3:54 AM
$ATRA
0 · Reply
GSP
GSP Mar. 12 at 9:28 PM
$SPY $ACXP $SOC $ATRA $AIB
0 · Reply
Niddi
Niddi Mar. 12 at 5:45 PM
$ATRA This is going to fly over next few weeks given that the meeting will be held around end of March with subsequent update/resubmission of documents required by FDA during the meeting.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 12 at 12:34 PM
$ATRA (+4.3% pre) FDA to review new tab-cel data after Atara partner seeks clarity https://ooc.bz/l/96440
0 · Reply
ballyhooo
ballyhooo Mar. 12 at 12:18 PM
$ATRA Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel “We are pleased that the FDA has granted a Type A Meeting to our partner, Pierre Fabre , and hope to gain clarity on a path forward for re-submission of the tab-cel BLA,” said Cokey Nguyen , President and Chief Executive Officer of Atara. “We anticipate providing a regulatory update in the second quarter.”
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 12 at 11:34 AM
$ATRA
0 · Reply
Niddi
Niddi Mar. 11 at 3:08 PM
$ATRA Type A meetings with FDA are scheduled within 30 days of request submission if FDA accepts it. This is very significant especially in light of recent announcement of change is FDA leadership. I am very optimistic.
0 · Reply